Cerebrolysin

Cerebrolysin is a porcine-brain–derived peptide preparation manufactured by EVER Pharma (Austria), containing low-molecular-weight neuropeptides and free amino acids and marketed for neurorestoration after ischaemic stroke, traumatic brain injury, and vascular or Alzheimer dementia. It is authorized as a prescription medicine in roughly 50 countries — including Austria, Germany (national authorization), Russia, China, and several CEE and Asian markets — but has no centralized EMA approval and is not FDA-approved. The Cochrane review by Ziganshina et al. (2017, most recently updated 2023, pub7) on acute ischaemic stroke found no demonstrable clinical benefit and a signal of more non-fatal serious adverse events; meta-analyses in vascular dementia and TBI show small, heterogeneous effects on cognitive scales. Use as a longevity or general anti-aging intervention is off-label and unsupported by current trial evidence.